FEDERAL COURT OF AUSTRALIA
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 3) [2011] FCAFC 165
Citation: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 3) [2011] FCAFC 165 Appeal from: Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2010] FCA 1211 Parties: SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LIMITED ACN 004 118 594 v WYETH AND WYETH AUSTRALIA PTY LIMITED ACN 000 296 211
ALPHAPHARM PTY LIMITED ACN 002 359 739
v WYETH AND WYETH AUSTRALIA PTY LIMITED ACN 000 296 211GENERIC HEALTH PTY LTD ACN 110 617 859
v WYETH AND WYETH AUSTRALIA PTY LIMITED ACN 000 296 211File numbers: NSD 1533 of 2010
NSD 1603 of 2010
NSD 1644 of 2010Judges: BENNETT, NICHOLAS AND YATES JJ Date of judgment: 21 December 2011 Catchwords: PRACTICE AND PROCEDURE – where interlocutory injunctions granted until trial of proceeding or further order – where permanent injunctions granted – where parties who obtained interlocutory injunctions released from their usual undertakings as to damages – not appropriate to grant such releases – usual undertakings as to damages should have been left in place so that they might operate in accordance with their terms – where orders granting permanent injunctions set aside on appeal – orders of primary judge releasing parties who obtained interlocutory injunctions from usual undertakings as to damages set aside
PRACTICE AND PROCEDURE – application for a stay of orders revoking claims of patent – where various undertakings including undertakings as to damages proffered by parties seeking stay – whether party seeking stay of order revoking claims of patent required to give undertaking as to damages – not usual to require such an undertaking – stay granted
Cases cited: Doric Products Pty Ltd v Lockwood Security Products Pty Ltd (2002) 54 IPR 495
Dr Martens Australia Pty Ltd v Figgins Holdings Pty Ltd (No 2) [2000] FCA 602
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 2) [2011] FCAFC 143
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2010] FCA 1258
Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth [2011] FCAFC 132Date of hearing: 23 November 2011 Date of last submissions: 30 November 2011 Place: Sydney Division: GENERAL DIVISION Category: Catchwords Number of paragraphs: 43 Counsel for the First Appellant: Mr D Shavin QC with Ms H Rofe Solicitor for the First Appellant: Griffith Hack Counsel for the Second Appellant: Mr SCG Burley SC and Mr P Flynn Solicitor for the Second Appellant: Mallesons Stephen Jaques Counsel for the Third Appellant: Ms A Bowne SC Solicitor for the Third Appellant: Middletons Counsel for the Respondents: Mr AJL Bannon SC and Mr C Dimitriadis Solicitor for the Respondents: Jones Day Counsel for Pharmathen S.A. and Pharmathen Industrial S.A. Mr MJ Darke Solicitor for Pharmathen S.A. and Pharmathen Industrial S.A. Corrs Chambers Westgarth
IN THE FEDERAL COURT OF AUSTRALIA
NEW SOUTH WALES DISTRICT REGISTRY
GENERAL DIVISION
NSD 1533 of 2010
ON APPEAL FROM THE FEDERAL COURT OF AUSTRALIA
BETWEEN: SIGMA PHARMACEUTICALS (AUSTRALIA) PTY LTD ACN 004 118 594
AppellantAND: WYETH
First RespondentWYETH…
Keep reading for free
Create a free CaseChat account to read Sigma Pharmaceuticals (Australia) Pty Ltd v Wyeth (No 3) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2011] FCAFC 165
- Decision Date
CaseChat Overview and Summary
In its reasoning, the court found that the interlocutory injunctions granted until the trial of the proceeding or further order were not appropriate, and therefore, the usual undertakings as to damages should have been left in place. Additionally, the court held that it was not usual to require a party seeking a stay of an order revoking claims of patent to give an undertaking as to damages. Consequently, the orders granting permanent injunctions were set aside on appeal, as well as the orders of the primary judge releasing the parties who obtained the interlocutory injunctions from the usual undertakings as to damages.
The court also granted a stay of the orders revoking claims of patent, upon the respondents providing various undertakings, including undertakings as to damages. The final orders of the court declared that each of claims 1 to 17 of the Australian Patent No 2003259586 was invalid, and claim 27 of the Patent was invalid to the extent that it was dependent upon any of claims 1 to 17. The court further ordered that claims 1 to 17 of the Patent be revoked, the cross-claim be dismissed, and any application for compensation be remitted to the primary judge for determination. The respondents were also required to pay a portion of the appellant's costs, and the Commissioner of Patents was directed to rectify the Register of Patents. Additionally, the stay of the orders for revocation and the release from the undertakings as to damages were subject to certain conditions and undertakings provided by the respondents.
Orders
Orders of the court
1. The declaration made by the primary judge on 8 November 2010 in proceeding number VID 195 of 2009 (the Sigma Proceeding) be set aside.
2. Orders 5, 8, 9, 10 and 11 made by the primary judge on 8 November 2010 in the Sigma Proceeding be set aside.
3. Order 6 made by the primary judge on 8 November 2010 in the Sigma Proceeding be set aside in so far as it releases the respondents from the undertakings as to damages given by them to the Court on 3 June 2009.
THE COURT DECLARES THAT:
4. Each of claims 1 to 17 (inclusive) of the Australian Patent No 2003259586 (the Patent) is invalid.
5. Claim 27 of the Patent is invalid to the extent that it is dependent upon any of claims 1 to 17 (inclusive) of the Patent.
THE COURT FURTHER ORDERS THAT:
6. Claims 1 to 17 (inclusive) of the Patent be revoked.
7. The cross-claim be dismissed.
8. Any application that has or may be made by any person seeking an order for the payment of compensation pursuant to the undertaking as to damages given by the respondents to the Court on 3 June 2009 be remitted to the primary judge for determination.
9. The respondents pay 80% of the appellant’s costs of the Sigma Proceeding and 80% of the appellant’s costs of the appeal.
AND THE COURT DIRECTS:
10. The Commissioner of Patents to rectify the Register of Patents to record that each of claims 1 to 17 (inclusive) of the Patent has been revoked.
AND THE COURT FURTHER ORDERS:
11. Upon the respondents undertaking to the Court as a condition of the making of this order:
(a) to prosecute the application for special leave (and if granted, the appeal) expeditiously;
(b) forthwith to serve on the Commissioner of Patents copies of these orders pursuant to s 140 of the Patents Act 1990 (Cth) (the Act) with a request that particulars of the order for revocation of claims 1-17 of the Patent and any order staying that order be registered in accordance with s 187 of the Act;
(c) not to, during the period of the stay, threaten any person with or commence or prosecute proceedings for infringement of claims 1 to 17 and claim 27 (insofar as it is dependent on claims 1 to 17) of the Patent (for the avoidance of doubt, the Respondents do not undertake not to seek relief in respect of infringements occurring during the period of the stay should these claims ultimately be held to be valid);
(d) not to, during the period of the stay, seek to amend claims 1 to 17 of the Patent otherwise than in the course of or in connection with these proceedings;
(e) not to, during the period of the stay or in any event before 1 April 2012, make any application to delist Efexor-XR from the Pharmaceutical Benefits Scheme (the PBS); and
(f) to submit to such order (if any) as the Court may consider to be just for the payment of compensation, to be assessed by the Court or as it may direct, to any party to Proceedings NSD 1533, 1603 and 1644 of 2010 adversely affected by the operation of the stay and to pay such compensation to that party:-
Order 6 and order 10 above be stayed:
(a) initially for a period of 28 days from today;
(b) if an application for leave to appeal is lodged within that period, until the determination of that application; and
(c) if special leave is granted, until the determination of the appeal.
12. Subject to the respondents providing the undertaking referred to in paragraph 11(e) above the respondents are released from the undertaking given by them to the primary judge on 8 November 2010 in the Sigma Proceeding not to make any application to delist Efexor-XR from the PBS.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011
1. The declaration made by the primary judge on 8 November 2010 in proceeding number NSD 596 of 2009 (the Alphapharm Proceeding) be set aside.
2. Orders 5, 8, 9, 10 and 11 made by the primary judge on 8 November 2010 in the Alphapharm Proceeding be set aside.
3. Order 6 made by the primary judge on 8 November 2010 in the Alphapharm Proceeding be set aside in so far as it releases the respondents from the undertakings as to damages given by them to the Court on 25 August 2009.
THE COURT DECLARES THAT:
4. Each of claims 1 to 17 (inclusive) of the Australian Patent No 2003259586 (the Patent) is invalid.
5. Claim 27 of the Patent is invalid to the extent that it is dependent upon any of claims 1 to 17 (inclusive) of the Patent.
THE COURT FURTHER ORDERS THAT:
6. Claims 1 to 17 (inclusive) of the Patent be revoked.
7. The cross-claim be dismissed.
8. Any application that has or may be made by any person seeking an order for the payment of compensation pursuant to the undertaking as to damages given by the respondents to the Court on 25 August 2009 be remitted to the primary judge for determination.
9. The respondents pay 80% of the appellant’s costs of the Alphapharm Proceeding and 80% of the appellant’s costs of the appeal.
AND THE COURT DIRECTS:
10. The Commissioner of Patents to rectify the Register of Patents to record that each of claims 1 to 17 (inclusive) of the Patent has been revoked.
AND THE COURT FURTHER ORDERS:
11. Upon the respondents undertaking to the Court as a condition of the making of this order:
(a) to prosecute the application for special leave (and if granted, the appeal) expeditiously;
(b) forthwith to serve on the Commissioner of Patents copies of these orders pursuant to s 140 of the Patents Act 1990 (Cth) (the Act) with a request that particulars of the order for revocation of claims 1-17 of the Patent and any order staying that order be registered in accordance with s 187 of the Act;
(c) not to, during the period of the stay, threaten any person with or commence or prosecute proceedings for infringement of claims 1 to 17 and claim 27 (insofar as it is dependent on claims 1 to 17) of the Patent (for the avoidance of doubt, the Respondents do not undertake not to seek relief in respect of infringements occurring during the period of the stay should these claims ultimately be held to be valid);
(d) not to, during the period of the stay, seek to amend claims 1 to 17 of the Patent otherwise than in the course of or in connection with these proceedings;
(e) not to, during the period of the stay or in any event before 1 April 2012, make any application to delist Efexor-XR from the Pharmaceutical Benefits Scheme (the PBS); and
(f) to submit to such order (if any) as the Court may consider to be just for the payment of compensation, to be assessed by the Court or as it may direct, to any party to Proceedings NSD 1533, 1603 and 1644 of 2010 adversely affected by the operation of the stay and to pay such compensation to that party:-
Order 6 and order 10 above be stayed:
(a) initially for a period of 28 days from today;
(b) if an application for leave to appeal is lodged within that period, until the determination of that application; and
(c) if special leave is granted, until the determination of the appeal.
12. Subject to the respondents providing the undertaking referred to in paragraph 11(e) above the respondents are released from the undertaking given by them to the primary judge on 8 November 2010 in the Alphapharm Proceeding not to make any application to delist Efexor-XR from the PBS.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011
1. The declaration made by the primary judge on 8 November 2010 in proceeding number NSD 1124 of 2009 (the Generic Health Proceeding) be set aside.
2. Orders 5, 8, 9, 10 and 11 made by the primary judge on 8 November 2010 in the Generic Health Proceeding be set aside.
3. Order 6 made by the primary judge on 8 November 2010 in the Generic Health Proceeding be set aside in so far as it releases the respondents from the undertakings as to damages given by them to the Court on 10 November 2009.
THE COURT DECLARES THAT:
4. Each of claims 1 to 17 (inclusive) of the Australian Patent No 2003259586 (the Patent) is invalid.
5. Claim 27 of the Patent is invalid to the extent that it is dependent upon any of claims 1 to 17 (inclusive) of the Patent.
THE COURT FURTHER ORDERS THAT:
6. Claims 1 to 17 (inclusive) of the Patent be revoked.
7. The cross-claim be dismissed.
8. Any application that has or may be made by any person seeking an order for the payment of compensation pursuant to the undertaking as to damages given by the respondents to the Court on 10 November 2009 be remitted to the primary judge for determination.
9. The respondents pay:
(a) 80% of the appellant’s costs of the Generic Health Proceeding; and
(b) the appellant’s costs of the appeal.
AND THE COURT DIRECTS:
10. The Commissioner of Patents to rectify the Register of Patents to record that each of claims 1 to 17 (inclusive) of the Patent has been revoked.
AND THE COURT FURTHER ORDERS:
11. Upon the respondents undertaking to the Court as a condition of the making of this order:
(a) to prosecute the application for special leave (and if granted, the appeal) expeditiously;
(b) forthwith to serve on the Commissioner of Patents copies of these orders pursuant to s 140 of the Patents Act 1990 (Cth) (the Act) with a request that particulars of the order for revocation of claims 1-17 of the Patent and any order staying that order be registered in accordance with s 187 of the Act;
(c) not to, during the period of the stay, threaten any person with or commence or prosecute proceedings for infringement of claims 1 to 17 and claim 27 (insofar as it is dependent on claims 1 to 17) of the Patent (for the avoidance of doubt, the Respondents do not undertake not to seek relief in respect of infringements occurring during the period of the stay should these claims ultimately be held to be valid);
(d) not to, during the period of the stay, seek to amend claims 1 to 17 of the Patent otherwise than in the course of or in connection with these proceedings;
(e) not to, during the period of the stay or in any event before 1 April 2012, make any application to delist Efexor-XR from the Pharmaceutical Benefits Scheme (the PBS); and
(f) to submit to such order (if any) as the Court may consider to be just for the payment of compensation, to be assessed by the Court or as it may direct, to any party to Proceedings NSD 1533, 1603 and 1644 of 2010 adversely affected by the operation of the stay and to pay such compensation to that party:-
Order 6 and order 10 above be stayed:
(a) initially for a period of 28 days from today;
(b) if an application for leave to appeal is lodged within that period, until the determination of that application; and
(c) if special leave is granted, until the determination of the appeal.
12. Subject to the respondents providing the undertaking referred to in paragraph 11(e) above the respondents are released from the undertaking given by them to the primary judge on 8 November 2010 in the Generic Health Proceeding not to make any application to delist Efexor-XR from the PBS.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.